Could the Will Smith "Incident" Involving Alopecia be Free Publicity for Pfizer’s Soon-to-Be Approved Medication for the Hair-Loss Condition?

Arheel's Uncle

Senior Reporter

Hollywood is Just One Long Informercial Nowadays; Could the Will Smith "Incident" Involving Alopecia be Free Publicity for Pfizer’s Soon-to-Be Approved Medication for the Hair-Loss Condition?​


By R.C.
Wed, Mar 30, 2022 9:21 p.m.

Could the ‘incident’ involving alopecia be free publicity for Pfizer’s soon-to-be approved medication for the hair loss condition?

Guess Who Were Proud Sponsors of the oscars?


‘Tis true.

Hollywood is just one long informercial nowadays.

============================================================

April 2021

March 2022

=============================================

As noted in Pfizer’s documents, Alopecia Areata is listed as one of the potential side effects of the COVID-19 shot.
 
Last edited:
It is a lie, their hair loss is from fake hair and chemicals or glues. They'll never admit it.
No drug will stop hair loss caused by fake hair.


Glue extensions, as well as double-sided tape, are often used with popular lace wigs. Unfortunately, they can cause damage that is often permanent. The glue can block your scalp pores and damage your hair follicles as well as burn and dry out your hair. The weight of the extensions can pull on your scalp which again can result in thinning hair. Sometimes these extensions can also cause headaches and bald spots.

Traction alopecia (TA) affects one-third of women of African descent who wear various forms of traumatic hairstyling for a prolonged period of time. The risk of TA is increased by the extent of pulling and duration of traction, as well as the use of chemical relaxation.


However, traction alopecia, a type of hair loss, is especially common among black women. According to dermatologist Crystal Aguh, who specializes in hair loss, nearly 50% of black women experience some form of hair loss.
 
Last edited:

Pfizer Receives Breakthrough Therapy Designation from FDA ...

https://www.pfizer.com › news › press-release › press-release-detail › pfizer_receives_breakthrough_therapy_designation_from_fda_for_pf_06651600_an_oral_jak3_inhibitor_for_the_treatment_of_patients_with_alopecia_areata

)--Pfizer Inc. (NYSE:pFE) today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body. 1,2
 
Last edited:
6 minutes


 
Last edited:
Back
Top